137 related articles for article (PubMed ID: 2120548)
21. Acute troglitazone action in isolated perfused rat liver.
Preininger K; Stingl H; Englisch R; Fürnsinn C; Graf J; Waldhäusl W; Roden M
Br J Pharmacol; 1999 Jan; 126(1):372-8. PubMed ID: 10051158
[TBL] [Abstract][Full Text] [Related]
22. Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats.
Santuré M; Pitre M; Nadeau A; Bachelard H
Metabolism; 2003 Aug; 52(8):978-86. PubMed ID: 12898461
[TBL] [Abstract][Full Text] [Related]
23. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Khoursheed M; Miles PD; Gao KM; Lee MK; Moossa AR; Olefsky JM
Metabolism; 1995 Nov; 44(11):1489-94. PubMed ID: 7476339
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone (CS-045): a new antidiabetic agent.
Kaneko T
Horm Metab Res; 1997 May; 29(5):203-13. PubMed ID: 9228204
[No Abstract] [Full Text] [Related]
25. Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells.
Asano T; Wakisaka M; Yoshinari M; Nakamura S; Doi Y; Fujishima M
Metabolism; 2000 Mar; 49(3):308-13. PubMed ID: 10726906
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone action is independent of adipose tissue.
Burant CF; Sreenan S; Hirano K; Tai TA; Lohmiller J; Lukens J; Davidson NO; Ross S; Graves RA
J Clin Invest; 1997 Dec; 100(11):2900-8. PubMed ID: 9389757
[TBL] [Abstract][Full Text] [Related]
27. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells.
Yasunari K; Kohno M; Kano H; Yokokawa K; Minami M; Yoshikawa J
Circ Res; 1997 Dec; 81(6):953-62. PubMed ID: 9400375
[TBL] [Abstract][Full Text] [Related]
29. Combined effects of troglitazone and muscle contraction on insulin sensitization in Balb-c mouse muscle.
Vander Lugt JT; Gómez-Márquez J; Caldon J; Louters LL
Biochimie; 2001 May; 83(5):445-51. PubMed ID: 11368854
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone upregulates LDL receptor activity in HepG2 cells.
Al Rayyes O; Florén CH
Diabetes; 1998 Aug; 47(8):1193-8. PubMed ID: 9703316
[TBL] [Abstract][Full Text] [Related]
31. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Miles PD; Romeo OM; Higo K; Cohen A; Rafaat K; Olefsky JM
Diabetes; 1997 Nov; 46(11):1678-83. PubMed ID: 9356012
[TBL] [Abstract][Full Text] [Related]
32. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts.
Kellerer M; Kroder G; Tippmer S; Berti L; Kiehn R; Mosthaf L; Häring H
Diabetes; 1994 Mar; 43(3):447-53. PubMed ID: 7508875
[TBL] [Abstract][Full Text] [Related]
33. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
Sreenan S; Keck S; Fuller T; Cockburn B; Burant CF
Am J Physiol; 1999 Jun; 276(6):E1119-29. PubMed ID: 10362626
[TBL] [Abstract][Full Text] [Related]
34. [Troglitazone: its pharmacology and mechanism of action].
Horikoshi H; Fujiwara T
Nihon Rinsho; 1997 Nov; 55 Suppl():125-30. PubMed ID: 9434455
[No Abstract] [Full Text] [Related]
35. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
Fujiwara T; Wada M; Fukuda K; Fukami M; Yoshioka S; Yoshioka T; Horikoshi H
Metabolism; 1991 Nov; 40(11):1213-8. PubMed ID: 1943750
[TBL] [Abstract][Full Text] [Related]
36. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
Miles PD; Higo K; Romeo OM; Lee MK; Rafaat K; Olefsky JM
Diabetes; 1998 Mar; 47(3):395-400. PubMed ID: 9519745
[TBL] [Abstract][Full Text] [Related]
37. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
38. Prolonged effect of troglitazone (CS-045) on xenograft survival of hybrid artificial pancreas.
Kawakami Y; Inoue K; Tun T; Hayashi H; Setoyama H; Gu YJ; Cui WX; Imamura M; Iwata H; Ikada Y
Cell Transplant; 1997; 6(5):547-50. PubMed ID: 9331511
[TBL] [Abstract][Full Text] [Related]
39. CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes.
Murano K; Inoue Y; Emoto M; Kaku K; Kaneko T
Eur J Pharmacol; 1994 Mar; 254(3):257-62. PubMed ID: 8013560
[TBL] [Abstract][Full Text] [Related]
40. [Studies on compounds with antioxidant activity--development of hypoglycemic agents, troglitazone (CS-045)].
Yoshioka T; Fujita T
Yakugaku Zasshi; 1997 Sep; 117(9):597-610. PubMed ID: 9357328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
